Navigation Links
Difficult to Treat Erectile Dysfunction Patients
Date:1/6/2008

Real Medicine Now

CHERRY HILL, N.J., Jan. 7 /PRNewswire/ -- TriMix Laboratories LLC today announced the introduction of TriMix-gel(TM). TriMix-gel(TM) has been suggested as an alternative for patients who fail on Viagra(R) type pills and cannot or will not self inject with a needle. With twenty million American men currently suffering with ED, current treatments are sufficient in many cases, but there remain more and more men who can't tolerate the side effects of Viagra(R) type pills and cannot bring themselves to self inject with a needle.

TriMix-gel(TM) is not an herbal remedy. It contains prescription medications listed in the US Pharmacopoeia. The active ingredients in this compounded medicine, prostaglandin, papaverine and phentolamine, have been tested and widely prescribed by physicians for many years.

Typically, trimix for injection would have to be refrigerated and then self injected at time of use. But this new compound in gel form called TriMix- gel(TM), allows the patient to carry the medicine on his person at room temperature. More importantly, an ED patient will not have to use a needle to self inject himself before sexual intercourse.

TriMix-gel(TM) doesn't require needles because it uses a novel methodology. At the time of use, before sexual intercourse, the patient uses an "all-in-one" application device which stores, mixes and applies the medicine. The patient does not need a needle for self injection. And the medicine does not require refrigeration.

To obtain the medicine, a patient needs to visit his physician for a thorough ED examination and if appropriate, the patient will be prescribed this medicine by his own doctor. The doctor can fax the prescription to the pharmacy (877-387-4649) and the pharmacy will ship the medicine directly to the patient. Applied Pharmacy Services, Inc., a licensed pharmacy in Mobile, AL has been chosen as the exclusive compounding pharmacy for TriMix-gel(TM) (877-887-4649).

T.J. Harkins, President of TriMix Laboratories says, "Physicians have been looking for a new delivery method for these medications for a long time and TriMix-gel(TM) is exactly what ED patients have been asking for."

The profession of pharmacy has always been based on the patient-physician- pharmacist relationship, known as the "Triad." Through this "Triad" relationship, patient needs are determined by a physician, who chooses a treatment regimen that may include a compounded medication. Physicians often prescribe compounded medications for various reasons, such as when a patient cannot ingest a medication in its available form. A pharmacist can prepare the medication in cream, liquid, gel or other form that the patient can more easily take.

TriMix Laboratories LLC is a medical research and marketing firm specializing in the urological subspecialty of erectile dysfunction. Applied Pharmacy is a recognized leader in pharmaceutical compounding, helping Physicians and Veterinarians with medicine precisely customized for each individual patient. Applied Pharmacy maintains federal and state licenses and permits and is registered to dispense in almost all states. For more information, visit http://www.TriMix-gel.com.

This press release contains forward-looking statements. These statements involve risks and uncertainties which may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed and actual results may differ materially. Ingredients in TriMix- gel(TM) are FDA approved but TriMix-gel(TM) is a custom compound made in a pharmacy and therefore has not been approved by the FDA for treatment of ED. TriMix-gel(TM) requires a valid prescription from a physician. You should discuss the risks and side effects associated with this drug with your physician. Before taking any action, consult your physician.

Contact:

TJ Harkins

TriMix Laboratories

Cherry Hill, NJ

856-755-3600


'/>"/>
SOURCE TriMix Laboratories LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IBM and Imago find a crucial difficulty in semiconductor device scaling
2. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... Weeks after hosting a carpal tunnel syndrome workshop with Dr. Oz on the ... the Fitzmaurice Hand Institute, has announced the addition of MRI diagnostic imaging services on ... 1 of about 3 currently available in the United States. Developed specifically for the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Doctors in Italy, Japan, the UK ... the BRCA-1 associated protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma ... to read the full article now. , The studies analyzed for the new ...
(Date:5/27/2016)... May 27, 2016 At present, the ... in this space know that volatility is what makes this ... on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ), ... (NASDAQ: LPTN ), and Heat Biologics Inc. (NASDAQ: ... to the technical alerts for these stocks at: ...
(Date:5/26/2016)... ISELIN, New Jersey and ... -- Indegene ( http://www.indegene.com ), a ... solutions to life science, pharmaceutical and healthcare organisations ... provider of innovative scientific support throughout the product ... alliance with the launch of IntraScience. ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):